Robert Hindes, MD, is the co-founder and chief medical officer of Trek Therapeutics. The Delaware-based public-benefit corporation aims to launch an affordable cure for the hepatitis C virus (HCV) in the year 2020. Robert Hindes, MD, is responsible for the development of the clinical strategy of the company, which is currently focused on developing two combination HCV therapies.
HCV is dangerous because patients often do not display any symptoms until their livers are considerably damaged. However, some patients develop symptoms associated with the virus within a few months of infection.
The symptoms include high temperature and tiredness, in addition to nausea and loss of appetite. More specific symptoms include the yellowing of the skin, often referred to as jaundice, which itchiness often accompanies. Some patients also suffer from sore muscles and joint pain and notice that their urine has become darker.
The challenge regarding these symptoms is that they may be associated with other conditions as well. That is why it is not uncommon for people to have HCV for over a decade without being aware they have contracted it.
HCV is dangerous because patients often do not display any symptoms until their livers are considerably damaged. However, some patients develop symptoms associated with the virus within a few months of infection.
The symptoms include high temperature and tiredness, in addition to nausea and loss of appetite. More specific symptoms include the yellowing of the skin, often referred to as jaundice, which itchiness often accompanies. Some patients also suffer from sore muscles and joint pain and notice that their urine has become darker.
The challenge regarding these symptoms is that they may be associated with other conditions as well. That is why it is not uncommon for people to have HCV for over a decade without being aware they have contracted it.